ETF Financing Ranking | GF CSI Innovative Drugs Industry ETF (515120) had a net financing buy-in of CNY 11.91 million, ranked first among comparable funds-20260602

Jun 2, 2026, GF CSI Innovative Drugs Industry ETF (515120.SH) decreased by 1.76%, had a turnover of CNY 367.16 million. Obtained financing buy-in of CNY 48.56 million, and financing repayment of CNY 36.65 million, with a net financing buy-in of CNY 11.91 million, ranked first among comparable funds. (Data source: Wind)

Over a longer period, had leveraged funds with continuous inflow over the last 2 days, with a total inflow of CNY 30.72 million, ranked top among comparable funds. (Data source: Wind)

GF CSI Innovative Drugs Industry ETF (515120.SH), off-exchange connection (A type: 012737; C type: 012738; F type: 022104).

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.